润肺膏联合氨溴特罗治疗儿童慢性支气管炎急性发作期的临床研究

Clinical study on Runfei Ointment combined with ambroxol and clenbuterol in treatment of chronic bronchitis during acute stage in children

目的 探讨润肺膏联合氨溴特罗口服溶液治疗儿童支气管炎的临床疗效。方法 选取石家庄市妇幼保健院在2021年2月—2024年1月收治的120例慢性支气管炎急性发作期患儿,按随机数字表法将所有患儿分为对照组和治疗组,每组各60例。对照组口服氨溴特罗口服液,2~3岁7.5 mL/次,4~5岁10 mL/次,6~12岁15 mL/次,12岁以上20 mL/次,2次/d。治疗组在对照组基础上开水冲服润肺膏,15 g/次,2次/d。两组持续治疗7 d。比较两组的临床疗效、症状缓解时间、通气功能指标和血清炎症指标。结果 治疗后,治疗组的总有效率(95.00%)明显高于对照组的总有效率(83.33%),差异有统计学意义(P<0.05)。治疗后,治疗组患儿发热、日间咳嗽、夜间咳嗽、喘息、肺啰音缓解时间均明显短于对照组,差异有统计学意义(P<0.05)。治疗后,两组的呼吸频率(BF)、吸气/呼气时间比(TI/TE)低于治疗前,潮气量(VT)高于治疗前(P<0.05);治疗组的BF、TI/TE低于对照组,VT高于对照组(P<0.05)。治疗后,两组的血清超敏C反应蛋白(hsCRP)、肿瘤坏死因子-α(TNF-α)水平低于治疗前,血清甘露糖结合凝集素(MBL)水平高于治疗前(P<0.05);治疗组的血清hs-CRP、TNF-α水平低于对照组,血清MBL水平高于对照组(P<0.05)。结论 润肺膏联合氨溴特罗口服溶液提高了儿童支气管炎的临床疗效,改善了临床症状和肺通气功能,减轻了炎症反应。

Objective To investigate the clinical effect of Runfei Ointment combined with Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution in treatment of chronic bronchitis during acute stage in children. Methods Children (120 cases) with chronic bronchitis during acute stage admitted to Shijiazhuang Maternal and Child Health Hospital from February 2021 to January 2024 were selected. All children were divided into control and treatment group using a random number table method, with 60 cases in each group. In the control group, children took Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution, 7.5 mL/time at the age of 2 to 3, 10 mL/time at the age of 4 to 5, 15 mL/time at the age of 6 to 12, and 20 mL/time at the age of 12 and above, twice daily. On the basis of the control group, the children in the treatment group were po administered with Runfei Ointment with boiled water for 15 g/times, twice daily. Children in both groups were treated for 7 days. The clinical efficacy, the symptom relief time, ventilation function index, and serum inflammation index were compared between two groups. Results After treatment, the total effective rate of the treatment group (95.00%) was significantly higher than that of the control group (83.33%), and the difference was statistically significant (P < 0.05). After treatment, the remission time of fever, daytime cough, nighttime cough, wheezing, and pulmonary rales in the treatment group was significantly shorter than those in the control group, and the difference was statistically significant (P < 0.05). After treatment, BF and TI/TE of two groups were lower than those before treatment, but VT of two groups was higher than those before treatment (P < 0.05). BF and TI/TE in the treatment group were lower than those in the control group, but VT in the treatment group was higher than those in the control group (P < 0.05). After treatment, the serum levels of hs-CRP and TNF-α were lower than before treatment, but the serum levels of MBL were higher than before treatment (P < 0.05). The serum levels of hs-CRP and TNF-α in the treatment group were lower than those in the control group, but the serum levels of MBL in the treatment group were higher than those in the control group (P < 0.05). Conclusion Runfei Semifluid Extract combined with Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution can improve the clinical effect of pediatric bronchitis, improve the efficiency of symptom improvement, reduce inflammation and improve lung ventilation function.